Compare
Belite Bio, Inc vs Spyre Therapeutics, Inc. vs Maravai Lifesciences Holdings, Inc. vs NewAmsterdam Pharma Co N.V.
| Latest fiscal year | Belite Bio, Inc BLTE | Spyre Therapeutics, Inc. SYRE | Maravai Lifesciences Holdings, Inc. MRVI | NewAmsterdam Pharma Co N.V. NAMS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $0 | $185.74M | $22.50M |
| Revenue growth (YoY) | n/a | n/a | -28.3% | -50.6% |
| Gross margin | n/a | n/a | 18.3% | n/a |
| Operating margin | n/a | n/a | -115.9% | n/m |
| Net margin | n/a | n/a | -70.4% | -905.7% |
| Net income | -$77.61M | -$155.20M | -$130.77M | -$203.82M |
| EPS (Diluted) | -$2.31 | n/a | -$0.90 | -$1.72 |
| Operating cash flow | -$36.99M | -$169.25M | -$57.57M | -$147.78M |
| Free cash flow | -$37.06M | n/a | -$70.72M | -$148.03M |
| Cash & equivalents | $352.93M | $85.72M | $216.89M | $490.00M |
| Total assets | $780.56M | $777.78M | $770.58M | $769.28M |
| Total liabilities | $10.07M | $62.55M | $397.87M | $85.85M |
| Shareholders' equity | $770.49M | $715.24M | $212.38M | $683.43M |
| Return on year-end equity | -10.1% | -21.7% | -61.6% | -29.8% |
| Shares outstanding | 39.34M | 78.19M | n/a | 114.40M |
Revenue, most recent five fiscal years
| Fiscal year | Belite Bio, Inc | Spyre Therapeutics, Inc. | Maravai Lifesciences Holdings, Inc. | NewAmsterdam Pharma Co N.V. |
|---|---|---|---|---|
| Latest | n/a | $0 Ended 2025-12-31 | $185.74M Ended 2025-12-31 | $22.50M Ended 2025-12-31 |
| 1 year earlier | n/a | $0 Ended 2024-12-31 | $259.19M Ended 2024-12-31 | $45.56M Ended 2024-12-31 |
| 2 years earlier | n/a | $886.0K Ended 2023-12-31 | $288.94M Ended 2023-12-31 | $14.09M Ended 2023-12-31 |
| 3 years earlier | n/a | $2.33M Ended 2022-12-31 | $883.00M Ended 2022-12-31 | $102.69M Ended 2022-12-31 |
| 4 years earlier | n/a | $18.74M Ended 2021-12-31 | $799.24M Ended 2021-12-31 | n/a |